Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erik S Linklater

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
The Journal of Cell Biology|May 17, 2021
Rab40-Cullin5 complex regulates EPLIN and actin cytoskeleton dynamics during cell migrationErik S Linklater, Emily D Duncan, Ke-Jun Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2015
Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC ModelsMansoureh Sameni, Elizabeth A Tovar, Curt J Essenburg, et al.
Molecular Cancer Research : MCR|July 5, 2013
MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistanceAmanda K Paulson, Erik S Linklater, Bree D Berghuis, et al.
Oncotarget|September 23, 2016
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancersErik S Linklater, Elizabeth A Tovar, Curt J Essenburg, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
The Journal of Cell Biology|May 17, 2021
Rab40-Cullin5 complex regulates EPLIN and actin cytoskeleton dynamics during cell migrationErik S Linklater, Emily D Duncan, Ke-Jun Han, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2015
Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC ModelsMansoureh Sameni, Elizabeth A Tovar, Curt J Essenburg, et al.
Molecular Cancer Research : MCR|July 5, 2013
MET and ERBB2 are coexpressed in ERBB2+ breast cancer and contribute to innate resistanceAmanda K Paulson, Erik S Linklater, Bree D Berghuis, et al.
Oncotarget|September 23, 2016
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancersErik S Linklater, Elizabeth A Tovar, Curt J Essenburg, et al.
Pageof 1